Related posts

Nervous markets await Nvidia
Investor Insights

This summary was created by AI, based on 17 opinions in the last 12 months.

Abbott Labs (ABT) is currently navigating some challenging legal landscapes while also showing promising growth potential across its diversified business segments, including medical devices and pharmaceuticals. The company has recently experienced positive momentum, with strong quarterly earnings and updated forecasts, countering some of the impacts of lawsuits related to its baby formula products. Experts note its solid fundamentals, particularly within its device business that has demonstrated robust organic growth. Despite facing legal challenges and penalties, many analysts are optimistic about the stock's trajectory in the long term, highlighting its reasonable valuation and consistent dividend growth. Overall, Abbott appears to be positioned well for future gains, even amid current litigation concerns.

Consensus
Positive
Valuation
Undervalued
BUY

They reported solid numbers today and considered raising their full-year forecast but then the tariffs hit, but maintained guidance, which is positive enough in this market. Shares jumped 2.76% today. A weaker USD helps too.

WATCH

It reports Wednesday. They will report on their strong franchises and their baby formula lawsuit which would have hurt their valuation for a long time. Not long ago, this was 14 points higher during that brutal, ridiculous rotation. These stocks are now all the way down.

WEAK BUY

He was looking at defensive healthcare names to avoid threat of tariffs. This is one name to consider, reasonable valuation but good growth profile.

BUY

Is enjoying the rotation out of semis/tech stocks today, up 3.52%. It's been undervalued lately. Has more room to run; he expects the rotation to continue beyond today.

PAST TOP PICK
(A Top Pick May 09/23, Up 20%)

It is one of the more diversified lab equipment manufacturers. He really likes the medical part and sees growth there. Some of their components have slower growth.

BUY ON WEAKNESS

Is one of the stars of the JPMorgan conference. Shares have been growing in a straight line with growth in medical devices and pharmaceuticals.

HOLD

Pharma companies are always facing the patent wall, needing to spend R&D to innovate new drugs. Very difficult to predict the next blockbuster. He prefers and owns JNJ and ABT, as they're more diversified.

BUY

Has excellent fundamentals across four businesses, including best-in-class medical devices renown in cardiology. However, they face lawsuits over their similac formula which studies show is not harmful. It's unfair. It lost a lawsuit last summer and was hit a $495 million penalty. More lawsuits are coming, though the latest decision yesterday went in Abbott's favour. Last month, federal agencies found that the formula is not at fault. Two weeks ago, ABT reported a clean top and bottom line beat and raised their full-year forecast. Shares would have rallied more without the lawsuits.

PAST TOP PICK
(A Top Pick Oct 23/23, Up 25%)

Expects it to growth topline and bottom line going forward, usually around the 10% range. Sells branded generic drugs to EMs, medical devices, infant nutrition. Diabetes monitoring product has very good growth. Likes that it's diversified, well managed. Yield close to 3%, grown for over 50 consecutive years.

BUY

His favourite in this sector. They just delivered a monster quarter.

COMMENT

They report Wednesday. Are facing legal challenges that their baby formula kills, but last week the FDA and CDC cleared them. This could turn the tide.

BUY

They're turning around, given their immunotherapy pipeline, and their device and testing businesses are strong.

TOP PICK

Pharma is challenged on growth, whereas devices have robust growth. Its device business has grown exceptionally well, between 10-12% organically. Overhang has been unfavourable comparisons from Covid testing. Reasonable valuation for quite a good company. Yield is 2%.

(Analysts’ price target is $123.65)
COMMENT

They lost a major court case last Friday and have to pay nearly $500 million in damages over its formula for premature babies. He feels the verdict is an outrage. Their formula saves lives and doctors recommend it.

BUY ON WEAKNESS

They report on July 18. The company is doing very well, but they could lose a looming lawsuit. He wouldn't add more shares unless this breaks below $100.

Showing 1 to 15 of 201 entries

Abbott Labs(ABT-N) Rating

Ranking : 3 out of 5

Star iconStar iconStar iconStar empty iconStar empty icon

Bullish - Buy Signals / Votes : 2

Neutral - Hold Signals / Votes : 2

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 4

Stockchase rating for Abbott Labs is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Abbott Labs(ABT-N) Frequently Asked Questions

What is Abbott Labs stock symbol?

Abbott Labs is a American stock, trading under the symbol ABT-N on the New York Stock Exchange (ABT). It is usually referred to as NYSE:ABT or ABT-N

Is Abbott Labs a buy or a sell?

In the last year, 4 stock analysts published opinions about ABT-N. 2 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Abbott Labs.

Is Abbott Labs a good investment or a top pick?

Abbott Labs was recommended as a Top Pick by on . Read the latest stock experts ratings for Abbott Labs.

Why is Abbott Labs stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Abbott Labs worth watching?

4 stock analysts on Stockchase covered Abbott Labs In the last year. It is a trending stock that is worth watching.

What is Abbott Labs stock price?

On 2025-04-25, Abbott Labs (ABT-N) stock closed at a price of $128.85.